X4 Pharmaceuticals (XFOR) said Friday that its marketing authorization application for mavorixafor to treat WHIM syndrome has been validated for review by the European Medicines Agency.
The EMA previously granted mavorixafor orphan drug designation to treat WHIM syndrome, a rare genetic disease that impairs the body's immune system and is characterized by recurrent infections, skin warts, and an increased risk of cancer.
The treatment is sold in the US under the Xolremdi brand name following approval last April by the US Food and Drug Administration to treat WHIM syndrome in patients 12 years of age and older.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。